Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors.
about
Crystal Structure of Lysine Sulfonamide Inhibitor Reveals the Displacement of the Conserved Flap Water Molecule in Human Immunodeficiency Virus Type 1 ProteaseHIV protease inhibitors: a review of molecular selectivity and toxicityEvolutionary modeling of rate shifts reveals specificity determinants in HIV-1 subtypesGenotypic testing for human immunodeficiency virus type 1 drug resistance.A multifaceted analysis of HIV-1 protease multidrug resistance phenotypesInteraction of ritonavir-boosted tipranavir with loperamide does not result in loperamide-associated neurologic side effects in healthy volunteers.Mechanisms of pharmacokinetic and pharmacodynamic drug interactions associated with ritonavir-enhanced tipranavir.New anti-HIV agents and targets.Early factors in successful anti-HIV treatment.Tipranavir: a novel non-peptidic protease inhibitor for the treatment of HIV infection.Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitorsThe next generation of HIV/AIDS drugs: novel and developmental antiHIV drugs and targets.Tipranavir: a novel second-generation nonpeptidic protease inhibitor.Tipranavir: a protease inhibitor for multi-drug resistant HIV-1.Practical perspectives on the use of tipranavir in combination with other medications: lessons learned from pharmacokinetic studies.Tipranavir: a protease inhibitor for HIV salvage therapy.Review of tipranavir in the treatment of drug-resistant HIV.Analysis of HIV-1 CRF_01 A/E protease inhibitor resistance: structural determinants for maintaining sensitivity and developing resistance to atazanavirTipranavir-ritonavir genotypic resistance score in protease inhibitor-experienced patientsTipranavir in the protease inhibitors arena.Recent patents and emerging therapeutics for HIV infections: a focus on protease inhibitors.Comparison of drug resistance scores for tipranavir in protease inhibitor-naive patients infected with HIV-1 B and non-B subtypes.Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir.Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers.Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy.Tipranavir: a novel protease inhibitor for HIV therapyInhibitors of HIV-1 protease: 10 years afterNew HIV protease inhibitors for drug-resistant viruses
P2860
Q27646453-BE5153E6-65D1-4BDA-A615-84089DE07CBFQ28082749-2249BBAB-3B4C-499D-854C-ED5C6AAA966EQ28473878-C266305F-6D2C-4B26-9B7D-5C52D9A1885DQ33906239-A441A35B-5E73-4E4A-BC7B-ED3C8B60E6C0Q34102058-01A4E0B3-2834-49A5-B40B-B6E14E0A27ACQ34228277-36AC20DA-6E04-43D1-A745-A30FC169AB8EQ34633457-BA81F71C-EC92-461F-AF02-328D39372B0BQ34944447-23D48DFD-F444-4515-B685-463889CCB8D4Q35207282-C2A31E12-3E5C-42D3-9194-7CC1435117ABQ35570956-79E8CD72-15FC-4298-8C98-C5A1A032F06FQ35636029-6D97B328-915C-4766-8999-8F81D6703D3BQ35917148-FA646A38-1D49-4C32-9925-1BEEE1E3B08AQ36066195-68B9CE7B-4F63-401A-80D1-23EE738916B7Q36349653-1D386390-825C-4A0F-8056-2AF01A3D3D23Q36375914-CCCAAC06-AE2B-48CC-ABF5-2761D0920AA3Q36513619-AE231F22-02AC-4352-AF86-510100DEC86BQ36642990-8B8ACB78-81A2-4E9E-955E-59C7CDEEE4D7Q36841895-15325228-B23B-4A3A-8757-873C3A49D22CQ36870850-C64C3DEB-8254-4E67-AD11-6A635B3CEC9EQ37963591-9DB408D2-CCA0-4E99-9F24-93E451BF8DECQ38162985-74818A8D-58D5-4907-ADCF-EF7A1CACA2E7Q38726300-B67EDE3E-9B85-4AEB-B053-AB7AE033DB56Q39290078-6060149C-6D5B-4FCE-A40C-A5A6D8D9AAD7Q45245263-F8497741-4820-4593-A574-E3FBE2BCAA7EQ46933139-46E609AB-836C-4248-B2A1-915770A19BFAQ58388976-21F5333C-8DDA-47B9-B828-AB8BAF9DA1FDQ58389026-05088934-F998-4841-A5B6-0D7CC0EBA223Q58389032-D1580412-ECDB-4BBC-87BB-6611EFC5A3C5
P2860
Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Susceptibility to PNU-140690 ( ...... to other protease inhibitors.
@en
Susceptibility to PNU-140690
@nl
type
label
Susceptibility to PNU-140690 ( ...... to other protease inhibitors.
@en
Susceptibility to PNU-140690
@nl
prefLabel
Susceptibility to PNU-140690 ( ...... to other protease inhibitors.
@en
Susceptibility to PNU-140690
@nl
P2093
P2860
P1476
Susceptibility to PNU-140690 ( ...... to other protease inhibitors.
@en
P2093
A d'Arminio-Monforte
P Citterio
S Kurtagic
S La Seta Catamancio
P2860
P304
P356
10.1128/AAC.44.5.1328-1332.2000
P407
P577
2000-05-01T00:00:00Z